0001104659-20-097531.txt : 20200922 0001104659-20-097531.hdr.sgml : 20200922 20200821150509 ACCESSION NUMBER: 0001104659-20-097531 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 CORRESP 1 filename1.htm

SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, New York 10036

August 21, 2020

VIA EDGAR

Alan Campbell

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3561
Washington, D.C. 20549

Re:

SELLAS Life Sciences Group, Inc.
Registration Statement on Form S-3

Filed August 14, 2020

File No. 333-246333

Dear Mr. Campbell:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Monday, August 24, 2020, at 5:00 p.m., Eastern Time, or as soon as thereafter practicable.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Any questions should be addressed to Daniel A. Bagliebter, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 692-6856.

Thank you very much.

	Very truly yours,

	SELLAS Life Sciences Group, Inc.


	/s/ Angelos M. Stergiou
	By: Angelos M. Stergiou, M.D., Sc.D., h.c.
	Title: President and Chief Executive Officer